--- title: "Capricor 治療公司因第四季度虧損幅度超出預期而股價下跌" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/279082570.md" description: "Capricor Therapeutics 的股價下跌 8.6%，至 30.54 美元，此前報告第四季度虧損 3020 萬美元，遠超分析師預期的 50 萬美元收入和每股虧損 51 美分。該公司在本季度沒有產生任何收入，較去年同期的 1110 萬美元下降。Capricor 正在等待 FDA 對 Deramiocel 治療杜氏肌營養不良症的批准，預計將在 2026 年 8 月 22 日之前收到回覆" datetime: "2026-03-13T19:05:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279082570.md) - [en](https://longbridge.com/en/news/279082570.md) - [zh-HK](https://longbridge.com/zh-HK/news/279082570.md) --- # Capricor 治療公司因第四季度虧損幅度超出預期而股價下跌 By Elias Schisgall Shares of Capricor Therapeutics fell after the company posted a wider-than-expected loss in the fourth quarter after not bringing in any revenue. Shares were down 8.6% to $30.54 in Friday afternoon trading. The stock has more than doubled in value in the past year. The biotechnology company on Thursday posted a quarterly loss of $30.2 million, or 62 cents a share, compared with a loss of $7.12 million, or 16 cents a share, a year earlier. Capricor did not post any revenue during the quarter, compared with $11.1 million a year prior. The company said its primary sources of revenue were $40 million in upfront and first-development milestone payments and $10 million in second-development milestone payments per the company's distribution agreement with Nippon Shinyaku. Those payments were recognized as of year-end 2024, it said. Analysts surveyed by FactSet were expecting $500,000 in revenue and a loss of 51 cents a share. The company said it is continuing to work toward approval for Deramiocel to treat Duchenne muscular dystrophy. A biologics license application for the treatment is under review by the Food and Drug Administration, and the company expects a response from the agency by Aug. 22. Write to Elias Schisgall at elias.schisgall@wsj.com (END) Dow Jones Newswires March 13, 2026 14:48 ET (18:48 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. ### 相關股票 - [IXJ.US](https://longbridge.com/zh-HK/quote/IXJ.US.md) - [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md) - [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [CAPR.US](https://longbridge.com/zh-HK/quote/CAPR.US.md) - [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md) - [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md) - [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [VHT.US](https://longbridge.com/zh-HK/quote/VHT.US.md) - [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md) - [XLV.US](https://longbridge.com/zh-HK/quote/XLV.US.md) - [IHE.US](https://longbridge.com/zh-HK/quote/IHE.US.md) - [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md) - [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md) - [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md) ## 相關資訊與研究 - [鉅亨速報 - Factset 最新調查：阿里拉姆製藥 (ALNY-US) EPS 預估下修至 6.57 元，預估目標價為 447.00 元](https://longbridge.com/zh-HK/news/282708759.md) - [藥廠 AI 合作潮！諾和諾德攜手 OpenAI 股價走揚](https://longbridge.com/zh-HK/news/282755292.md) - [諾和諾德夥 OpenAI 研發藥物 AI 分析數據 識別具潛力候選藥](https://longbridge.com/zh-HK/news/282661383.md) - [生華科獲國際資本青睞 與 GEM 簽署 MOU 獲 5 億元額度支持新藥研發](https://longbridge.com/zh-HK/news/282645308.md) - [諾和諾德與 OpenAI 攜手，以 AI 加速開發肥胖與代謝藥物](https://longbridge.com/zh-HK/news/282666368.md)